Human papillomavirus vaccine for cancer cervix prevention: Rationale & recommendations for implementation in India

India contributed to one-fourth of the global burden of cervical cancer in 2000. [...]researchers emphasized the need for population-based interventions in India to reduce the overall burden of cervical cancer globally[3]. A multidisciplinary Expert Group constituted by the Secretary, Department of Health Research (DHR) and Director-General (DG), Indian Council of Medical Research, Ministry of Health and Family Welfare, Government of India, reviewed the available evidence globally regarding immunogenicity and efficacy, adverse effects and cost-effectiveness of the HPV vaccine. HPV infections, precancerous lesions and anogenital warts A systematic review of 20 studies from nine high-income countries analyzed the risk reduction in the HPV infection and anogenital warts in the vaccinated cohorts[9]. Protection is for only selected HPV types and does not cover all high-risk types. [...]comprehensive cervical cancer control also requires cervical cancer screening for early detection and treatment, even for those cohorts vaccinated against HPV.